Fetal Growth Restriction & Maternal Cardiovascular Risk
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00241683|
Recruitment Status : Completed
First Posted : October 19, 2005
Last Update Posted : January 21, 2013
|Condition or disease|
|Cardiovascular Diseases Heart Diseases|
Intrauterine growth restriction leads to major neonatal morbidity and mortality. Moreover, recent birth registry studies have suggested that women bearing IUGR babies may have an elevated risk of cardiovascular disease.
This cohort study tested whether exposed women, with a previous intrauterine growth restriction (IUGR) baby, versus unexposed women, with a pregnancy not complicated by IUGR, had elevations in markers of cardiovascular risk. Exposure was defined among a geographically defined cohort as having had a singleton baby in the < 5 %tile of weight for gestational age, in the absence of pre-pregnancy diabetes., hypertension, renal disease, or hypertension in pregnancy; controls had a singleton in the > 20%tile. Four to twelve years postpartum, women were assessed for multiple markers of cardiovascular risk, including blood pressure, lipids, adiposity, glucose and insulin, homocysteine and folate, markers of inflammation, markers of endothelial function, markers of angiogenesis, and markers of vascular function. Data analysis consisted of ANOVA and ANCOVA analyses comparing the outcomes of cardiovascular markers among exposed and unexposed women.
|Study Type :||Observational|
|Actual Enrollment :||704 participants|
|Official Title:||Fetal Growth Restriction & Maternal Cardiovascular Risk|
|Study Start Date :||August 2005|
|Actual Primary Completion Date :||April 2009|
|Actual Study Completion Date :||April 2009|
- Blood pressure [ Time Frame: 4 to 12 years after pregnancy ]
- Triglycerides and LDL cholesterol [ Time Frame: 4 to 12 years after pregnancy ]
- Glucose [ Time Frame: 4 to 12 years after pregnancy ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00241683
|Principal Investigator:||Roberta B. Ness, MD, MPH||The University of Texas Health Science Center, Houston|